Work

Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps4671

Authors: Andrew L. Coveler, David Lawrence Bajor, Ashiq Masood, Emrullah Yilmaz, Anthony Frank Shields, Milind M. Javle, Ravi Kumar Paluri, Gina M. Vaccaro, Mark Zalupski, Juneko E. Grilley-Olson, Hedy L. Kindler, Michael W. Schmitt, Martin Gutierrez

Institutions: Seattle Cancer Care Alliance, University of Washington, University Hospitals Cleveland Medical Center, Case Western Reserve University, Rush University, UNM Comprehensive Cancer Center, Wayne State University, The Barbara Ann Karmanos Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Alabama at Birmingham, Providence Portland Medical Center, University of Michigan, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, University of Chicago, Seagen (United States), Hackensack University Medical Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3032186706

Cites:

Cited by: 8

Related to: 10